Allergy Therapeutics (AGY)

 7.88p
   
  • Change Today:
      0.000p
  • 52 Week High: 15.63p
  • 52 Week Low: 7.74p
  • Currency: UK Pounds
  • Shares Issued: 406.91m
  • Volume: 50,221,642
  • Market Cap: £32.04m
  • RiskGrade: 148
  • Beta: 0.27

AGY Overview

Allergy Therapeutics is in the pharmaceuticals & biotechnology sector and is currently trading at 7.88p per share. In the last year Allergy Therapeutics's share price has ranged from 7.74p to 15.63p and brokers are currently rating this stock as 'strong buy'.

1 Day Chart (25-05-2012)

1 Day Chart

6 Month Chart

6 Month Chart

Financials

Latest F'cast
Div Yield 0.0% 0.0%
Div Cover n/a n/a
Op Mrgn 0.3% 1.3%
ROCE 0.9%  
Latest F'cast
P/E n/a 71.6
PEG n/a n/a
Pr/Revenue 0.8 0.7
Pr/Book 15.0  
Latest F'cast
Revenue 2.0% 3.2%
PBT n/a n/a
EPS n/a n/a
DPS n/a n/a

AGY Fundamentals

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
30-Jun-07 25.74 (25.76) (28.40)p n/a n/a n/a n/a 0.0%
30-Jun-08 31.02 (20.24) (24.80)p n/a n/a n/a n/a 0.0%
30-Jun-09 37.76 (11.44) (14.35)p n/a n/a n/a n/a 0.0%
30-Jun-10 40.75 (0.12) 0.20p 57.5 n/a n/a n/a 0.0%
30-Jun-11 41.55 (2.31) (0.86)p n/a n/a n/a n/a 0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

AGY Forecasts

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
30-Jun-12 42.90 0.57 0.11p 71.6 n/a n/a n/a 0.0%
30-Jun-13 47.55 2.28 0.46p 17.1 0.1 +318% n/a 0.0%

Copyright © 2012 FactSet Research Systems Inc. All rights reserved.

AGY Company Announcements

Voluntary recall of Anapen by Lincoln Medical 23-May-2012 11:23 RNS
Holding(s) in Company 17-May-2012 16:51 RNS
Holding(s) in Company 17-May-2012 16:51 RNS

Latest AGY Director Deals

No deals were found in the last 28 days.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

AGY Market Data

Currency UK Pounds
Share Price 7.88p
Change Today 0.000p
% Change 0.00 %
52 Week High 15.63p
52 Week Low 7.74p
Volume 50,221,642
Shares Issued 406.91m
Market Cap £32.04m
Beta 0.27
RiskGrade 148

AGY Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
88.3% below the market average88.3% below the market average88.3% below the market average88.3% below the market average88.3% below the market average
82.98% below the sector average82.98% below the sector average82.98% below the sector average82.98% below the sector average82.98% below the sector average
Price Trend
69.29% below the market average69.29% below the market average69.29% below the market average69.29% below the market average69.29% below the market average
71.43% below the sector average71.43% below the sector average71.43% below the sector average71.43% below the sector average71.43% below the sector average
Income Not Available
Growth
6.94% below the market average6.94% below the market average6.94% below the market average6.94% below the market average6.94% below the market average
22.45% below the sector average22.45% below the sector average22.45% below the sector average22.45% below the sector average22.45% below the sector average

What The Brokers Say

Strong Buy 1
Buy 0
Neutral 0
Sell 0
Strong Sell 0
Total 1
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

AGY Dividends

No dividends found

Trades for 25-May-2012

Time Volume / Share Price
16:39 10,000 @ 8.00p
16:30 16,732,764 @ 7.74p
16:28 10,000 @ 8.00p
16:19 16,732,764 @ 7.75p
16:19 16,732,764 @ 7.75p

AGY Key Personnel

Finance Director Ian D Postlewaite
CEO Manuel Llobet

Top of Page